Empirical Finance LLC Acquires 13,124 Shares of The Cooper Companies, Inc. $COO

Empirical Finance LLC lifted its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 193.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,908 shares of the medical device company’s stock after buying an additional 13,124 shares during the quarter. Empirical Finance LLC’s holdings in Cooper Companies were worth $1,428,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. California State Teachers Retirement System grew its position in Cooper Companies by 6,101.7% in the 2nd quarter. California State Teachers Retirement System now owns 19,460,014 shares of the medical device company’s stock valued at $1,395,478,000 after acquiring an additional 19,146,230 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Cooper Companies during the second quarter worth $1,077,762,000. State Street Corp boosted its stake in shares of Cooper Companies by 2.4% during the fourth quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock valued at $720,736,000 after purchasing an additional 207,195 shares during the period. Wellington Management Group LLP boosted its stake in shares of Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after purchasing an additional 4,756,178 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Cooper Companies by 58.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock worth $494,123,000 after purchasing an additional 2,231,568 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on COO. UBS Group began coverage on shares of Cooper Companies in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $75.00 price target on the stock. Stifel Nicolaus lowered their price objective on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Mizuho set a $85.00 target price on shares of Cooper Companies and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. Finally, Piper Sandler set a $86.00 price target on Cooper Companies and gave the company an “overweight” rating in a report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Cooper Companies presently has a consensus rating of “Hold” and an average target price of $81.64.

Cooper Companies Trading Down 6.2%

Shares of NASDAQ:COO opened at $63.48 on Thursday. The company has a market capitalization of $12.38 billion, a PE ratio of 53.80, a P/E/G ratio of 1.77 and a beta of 0.82. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a 12-month low of $58.89 and a 12-month high of $89.83. The business’s fifty day simple moving average is $72.42 and its 200-day simple moving average is $70.02.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the business posted $0.49 EPS. The firm’s quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities research analysts predict that The Cooper Companies, Inc. will post 4.63 earnings per share for the current fiscal year.

Cooper Companies announced that its board has authorized a share repurchase plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal Q3 non-GAAP EPS of $1.15, exceeding the $1.11-$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while GAAP EPS was $2.24, helped by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: Cash generation and capital returns were strong: free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock during the quarter. The board also expanded its share-repurchase authorization from $2 billion to $3 billion. CooperCompanies Completes Strategic Review
• Neutral Sentiment: CooperSurgical revenue rose 2% on a reported basis and 3% organically, but CooperVision revenue was unchanged year over year. Overall quarterly revenue growth was only about 1% and fell short of the roughly $1.10 billion consensus estimate.
• Negative Sentiment: Management guided fiscal 2026 non-GAAP EPS to $4.51-$4.55, below the $4.63 analyst consensus, with revenue guidance of $4.229-$4.252 billion. Fourth-quarter EPS guidance of $1.05-$1.09 was also well below the approximately $1.20 expected by analysts. The Cooper Companies Q3 Earnings Metrics
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because received offers were not sufficiently attractive. Investors may view this as a missed opportunity to unlock value, particularly amid valuation pressure from a new non-hormonal IUD competitor and fertility-related litigation costs. CooperCompanies Strategic Review and Buyback

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.